Adv Search
 
Electron J Metab Nutr Cancer
Current Issue | Archive | Adv Search |
Clinical study of thalidomide plus Icotinib hydrochloride in the treatment of advanced pulmonary adenocarcinoma
JIANG Qian, WANG Yi, SUN Xiang
Department of Oncology, The First People’s Hospital of Hefei(The Third Affiliated Hospital of Anhui Medical College), Hefei 230001, Anhui, China
Download: PDF (1252 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  Objective To observe the efficacy and toxicities of thalidomide plus icotinib in the treatment of advanced pulmonary adenocarcinoma. Methods Totally 63 patients with pulmonary adenocarcinoma in the third affiliated hospital of Anhui medical college were selected for study from January 2013 to June 2015. The patients were randomly divided into control and experimental groups, control group of 30 patients received icotinib; the experimental groups, 33 cases received thalidomide combined with icotinib. The clinical efficacy, adverse reactions, survival rate and the changes of the serum vascular endothelial growth factor (VEGF), interleukin-8(IL-8) tumor necrosis factor α (TNF-α); fibroblast growth factor (bFGF) of the two groups were observed and compared. Results No significant differences were found in adverse reactions, such as rash, diarrhea, abnormal liver and renal function and occurrence of bone narrow suppression of both groups. The incidence of occult blood of stool in experimental groups were higher than the control groups. The objective response rate (ORR) of the control group was 43.33%, while that of the experimental group was 69.70% (P<0.05). The PFS of the experimental group was 21.12±6.56 months, while that of the control group was 19.77±6.61 months (P=0.073). The VEGF levels in the control groups were significantly lower than the experimental groups 295.0 (122.67~572.54)vs 148.0 (56.33~337.42) pg/ml(P<0.01). IL-8, TNF-α and bFGF levels between the two groups (P=0.0585), there was no statistical difference. But IL-8 and TNF-α levels in the experimental group were lower than the control group, and bFGF levels in the experimental group were higher than the control group, suggesting a trend of difference between the two groups. Conclusion Thalidomide combining with icotinib hydrochloride is effective and well tolerated in patients with advanced pulmonary adenocarcinoma. It may be a rational choice for the standard and individualized treatment of advanced pulmonary adenocarcinoma.
Key wordsThalidomide      Icotinib hydrochloride      Pulmonary adenocarcinoma      Therapeutic evaluation      Adverse reactions     
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
JIANG Qian
WANG Yi
SUN Xiang
Cite this article:   
JIANG Qian,WANG Yi,SUN Xiang. Clinical study of thalidomide plus Icotinib hydrochloride in the treatment of advanced pulmonary adenocarcinoma[J]. Electron J Metab Nutr Cancer, 2019, 6(2): 216-220.
URL:  
http://182.92.200.144/EN/10.16689/j.cnki.cn11-9349/r.2019.02.012     OR     http://182.92.200.144/EN/Y2019/V6/I2/216
Copyright © Editorial Board of Electron J Metab Nutr Cancer
Supported by:Beijing Magtech